96 related articles for article (PubMed ID: 16756631)
1. Elimination and clearance of pamidronate by haemodialysis.
Buttazzoni M; Rosa Diez GJ; Jager V; Crucelegui MS; Algranati SL; Plantalech L
Nephrology (Carlton); 2006 Jun; 11(3):197-200. PubMed ID: 16756631
[TBL] [Abstract][Full Text] [Related]
2. Impact of automated peritoneal dialysis on initial graft function after renal transplantation.
Lobbedez T; Rognant N; Hurault de Ligny B; el Haggan W; Allard C; Ryckelync JP
Adv Perit Dial; 2005; 21():90-3. PubMed ID: 16686293
[TBL] [Abstract][Full Text] [Related]
3. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging?
Kumar V; Kumar D; Howman-Giles RB; Little DG
Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350
[TBL] [Abstract][Full Text] [Related]
4. How to start the late referred ESRD patient urgently on chronic APD.
Povlsen JV; Ivarsen P
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 2():ii56-9. PubMed ID: 16825263
[TBL] [Abstract][Full Text] [Related]
5. Hemodialyzability of sertraline.
Schwenk MH; Verga MA; Wagner JD
Clin Nephrol; 1995 Aug; 44(2):121-4. PubMed ID: 8529300
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.
Tsaganos T; Kouki P; Digenis P; Giamarellou H; Giamarellos-Bourboulis EJ; Kanellakopoulou K
Int J Antimicrob Agents; 2008 Jul; 32(1):46-9. PubMed ID: 18534825
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.
Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB
J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772
[TBL] [Abstract][Full Text] [Related]
8. Staff-assisted nursing home haemodialysis: patient characteristics and outcomes.
Reddy NC; Korbet SM; Wozniak JA; Floramo SL; Lewis EJ
Nephrol Dial Transplant; 2007 May; 22(5):1399-406. PubMed ID: 17259652
[TBL] [Abstract][Full Text] [Related]
9. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol.
Nüsken KD; Petrasch M; Rauh M; Stöhr W; Nüsken E; Schneider H; Dötsch J
Nephrol Dial Transplant; 2009 Sep; 24(9):2832-8. PubMed ID: 19389865
[TBL] [Abstract][Full Text] [Related]
10. Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis.
Lin YF; Huang JW; Wu MS; Chu TS; Lin SL; Chen YM; Tsai TJ; Wu KD
Nephrology (Carlton); 2009 Feb; 14(1):59-64. PubMed ID: 19019171
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of dyphylline elimination by uremic patients.
Lee CC; Wang LH; Majeske BL; Marbury TC
J Pharmacol Exp Ther; 1981 May; 217(2):340-4. PubMed ID: 7229976
[TBL] [Abstract][Full Text] [Related]
12. Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats.
Pongchaidecha M; Daley-Yates PT
Drug Metab Dispos; 1993; 21(1):100-4. PubMed ID: 8095201
[TBL] [Abstract][Full Text] [Related]
13. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis.
Burmeister JE; Scapini A; da Rosa Miltersteiner D; da Costa MG; Campos BM
Nephrol Dial Transplant; 2007 Apr; 22(4):1184-9. PubMed ID: 17272314
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
Robson R; Buttimore A; Lynn K; Brewster M; Ward P
Nephrol Dial Transplant; 2006 Sep; 21(9):2556-62. PubMed ID: 16799169
[TBL] [Abstract][Full Text] [Related]
15. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL
Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369
[TBL] [Abstract][Full Text] [Related]
16. Residual renal function in children treated with continuous ambulatory peritoneal dialysis or automated peritoneal dialysis--a preliminary study.
Roszkowska-Blaim M; Skrzypczyk P; Drozdz D; Pietrzyk JA
Adv Perit Dial; 2009; 25():103-9. PubMed ID: 19886329
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis.
Wong CF; McCarthy M; Howse ML; Williams PS
Ren Fail; 2007; 29(6):653-9. PubMed ID: 17763158
[TBL] [Abstract][Full Text] [Related]
18. Assessment of management and treatment responses in haemodialysis patients from Tehran province, Iran.
Mahdavi-Mazdeh M; Zamyadi M; Nafar M
Nephrol Dial Transplant; 2008 Jan; 23(1):288-93. PubMed ID: 17965435
[TBL] [Abstract][Full Text] [Related]
19. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration.
Gattringer R; Meyer B; Heinz G; Guttmann C; Zeitlinger M; Joukhadar C; Dittrich P; Thalhammer F
J Antimicrob Chemother; 2006 Aug; 58(2):367-71. PubMed ID: 16782745
[TBL] [Abstract][Full Text] [Related]
20. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
